2023
Outcomes of Infliximab-Treated inflammatory bowel disease patients undergoing therapeutic drug monitoring with two different assays
Al-Bawardy B, Jenkins S, Snyder M, Frinack J, Ladwig P, Loftus E, Willrich M. Outcomes of Infliximab-Treated inflammatory bowel disease patients undergoing therapeutic drug monitoring with two different assays. Clinical Biochemistry 2023, 119: 110618. PMID: 37507083, DOI: 10.1016/j.clinbiochem.2023.110618.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overChildChromatography, LiquidDrug MonitoringFemaleHumansInflammatory Bowel DiseasesInfliximabMaleMiddle AgedTandem Mass SpectrometryYoung AdultConceptsInflammatory bowel disease patientsBowel disease patientsEndoscopic healingClinical remissionDisease patientsMcg/Normal serum C-reactive proteinDrug monitoringSerum C-reactive proteinLC-MS/MSInfliximab drug levelsFavorable clinical outcomeC-reactive proteinTherapeutic drug monitoringIBD patientsNormal CRPClinical outcomesDrug levelsPatientsECLIARemissionDifferent assaysOutcomesMcgAssaysAssessment of Inflammatory Bowel Disease Training Among Gastroenterology Fellows
Al-Bawardy B, Malter L, Ehrlich A, Rieder F, Gaidos J, Proctor D, Windish D. Assessment of Inflammatory Bowel Disease Training Among Gastroenterology Fellows. Inflammatory Bowel Diseases 2023, 29: 1990-1992. PMID: 36810663, PMCID: PMC11491607, DOI: 10.1093/ibd/izad030.Peer-Reviewed Original ResearchOutcomes of immunomodulator and advanced therapies for primary sclerosing cholangitis-associated inflammatory bowel disease
Sayed A, Assis D, Silveira M, Deng Y, Ciarleglio M, Gaidos J, Proctor D, Al-Bawardy B. Outcomes of immunomodulator and advanced therapies for primary sclerosing cholangitis-associated inflammatory bowel disease. European Journal Of Gastroenterology & Hepatology 2023, 35: 270-274. PMID: 36708297, DOI: 10.1097/meg.0000000000002510.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultCholangitisCholangitis, SclerosingFemaleHumansImmunologic FactorsInflammatory Bowel DiseasesMaleMiddle AgedRetrospective StudiesRisk FactorsConceptsPrimary sclerosing cholangitisInflammatory bowel diseasePSC-IBDEndoscopic healingTherapy groupAdvanced therapiesClinical remissionBowel diseaseAcute ascending cholangitisRate of cholangitisSmall bowel involvementThird of patientsAscending cholangitisSclerosing cholangitisAdult patientsBowel involvementSecondary outcomesMedian agePrimary outcomeRetrospective studyHigh riskCholangitisPatientsTherapyLarger studyComparative Safety of Biologic Agents in Patients With Inflammatory Bowel Disease With Active or Recent Malignancy: A Multi-Center Cohort Study
Holmer A, Luo J, Russ K, Park S, Yang J, Ertem F, Dueker J, Nguyen V, Hong S, Zenger C, Axelrad J, Sofia A, Petrov J, Al-Bawardy B, Fudman D, Llano E, Dailey J, Jangi S, Khakoo N, Damas O, Barnes E, Scott F, Ungaro R, Singh S, Helping-IBD R. Comparative Safety of Biologic Agents in Patients With Inflammatory Bowel Disease With Active or Recent Malignancy: A Multi-Center Cohort Study. Clinical Gastroenterology And Hepatology 2023, 21: 1598-1606.e5. PMID: 36642291, DOI: 10.1016/j.cgh.2023.01.002.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBiological FactorsBiological ProductsHumansInflammatory Bowel DiseasesMiddle AgedNeoplasmsRetrospective StudiesTumor Necrosis Factor InhibitorsTumor Necrosis Factor-alphaConceptsNon-TNF biologicsInflammatory bowel diseaseProgression-free survivalRecurrence-free survivalTNFα antagonistsActive cancerPrior cancerCohort studyBiologic agentsBowel diseaseRecent cancerMulticenter retrospective cohort studyMulti-center cohort studyIBD disease severityRetrospective cohort studyChoice of biologicsTumor necrosis factorCohort BPrimary outcomeComparable safetyΑ antagonistsComparative safetyCancer recurrenceNecrosis factorPatients
2020
The Impact of Vedolizumab on Pre-Existing Extraintestinal Manifestations of Inflammatory Bowel Disease: A Multicenter Study
Ramos GP, Dimopoulos C, McDonald NM, Janssens LP, Hung KW, Proctor D, Ruggiero E, Kane S, Bruining DH, Faubion WA, Raffals LE, Loftus EV, Al-Bawardy B. The Impact of Vedolizumab on Pre-Existing Extraintestinal Manifestations of Inflammatory Bowel Disease: A Multicenter Study. Inflammatory Bowel Diseases 2020, 27: 1270-1276. PMID: 33165569, DOI: 10.1093/ibd/izaa293.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntibodies, Monoclonal, HumanizedArthritisFemaleHumansInflammatory Bowel DiseasesMaleMiddle AgedRetrospective StudiesConceptsInflammatory bowel diseaseExtraintestinal manifestationsPeripheral arthritisBowel diseaseDose of vedolizumabPrevious biologic useMulticenter retrospective studyCurrent medical therapyTerms of ageConcurrent immunosuppressantsCorticosteroid therapyVDZ treatmentIBD subtypesBiologic useSecondary outcomesMedical therapyPrimary outcomeClinical outcomesMulticenter studyRetrospective studyVedolizumabPatientsCommon typeDiscontinuationArthritis
2018
Findings of CT-Derived Bone Strength Assessment in Inflammatory Bowel Disease Patients Undergoing CT Enterography in Clinical Practice
Maldonado FJ, Bawardy BF, Nehra AK, Lee YS, Bruining DH, Adkins MC, Keaveny TM, Johnson MP, Fidler JL, McCollough CH, Fletcher JG. Findings of CT-Derived Bone Strength Assessment in Inflammatory Bowel Disease Patients Undergoing CT Enterography in Clinical Practice. Inflammatory Bowel Diseases 2018, 25: 1072-1079. PMID: 30476314, DOI: 10.1093/ibd/izy341.Peer-Reviewed Original ResearchConceptsBiomechanical CT analysisBone mineral densityHigh fracture riskHigh-risk groupFracture riskCT enterographyIBD patientsFemoral neck bone mineral densityInflammatory bowel disease patientsNeck bone mineral densityWorld Health Organization classificationConsecutive IBD patientsFracture risk classificationBowel disease patientsFindings of CTMetabolic bone diseaseRetrospective reviewClinical featuresExact prevalenceDisease patientsOrganization classificationMineral densityBone diseasePatientsClinical practiceVedolizumab Drug Level Correlation With Clinical Remission, Biomarker Normalization, and Mucosal Healing in Inflammatory Bowel Disease
Al-Bawardy B, Ramos GP, Willrich MAV, Jenkins SM, Park SH, Aniwan S, Schoenoff SA, Bruining DH, Papadakis KA, Raffals L, Tremaine WJ, Loftus EV. Vedolizumab Drug Level Correlation With Clinical Remission, Biomarker Normalization, and Mucosal Healing in Inflammatory Bowel Disease. Inflammatory Bowel Diseases 2018, 25: 580-586. PMID: 30165638, DOI: 10.1093/ibd/izy272.Peer-Reviewed Original ResearchConceptsMedian vedolizumab trough levelsVedolizumab trough levelsC-reactive proteinInflammatory bowel diseaseNormal C-reactive proteinMucosal healingCrohn's diseaseUC patientsBowel diseaseTrough levelsUlcerative colitisClinical managementFourth of patientsTrough level measurementMayo endoscopic scoreCross-sectional studyHigh CRP patientsBiomarker normalizationIBD patientsClinical remissionCRP patientsEndoscopic scoreMucosal ulcersDetectable antibodiesBACKGROUND/
2017
Inflammatory bowel disease: Clinical screening and transition of care
Al-Bawardy B. Inflammatory bowel disease: Clinical screening and transition of care. Saudi Journal Of Gastroenterology 2017, 23: 213-215. PMID: 28721973, PMCID: PMC5539673, DOI: 10.4103/sjg.sjg_294_17.Peer-Reviewed Case Reports and Technical Notes
2011
Missing cohort: Inflammatory bowel disease patients at increased risk for cervical dysplasia may be undervaccinated for HPV
Al-Bawardy B, Fine S, LaFond J, Doran A, Borum ML. Missing cohort: Inflammatory bowel disease patients at increased risk for cervical dysplasia may be undervaccinated for HPV. Inflammatory Bowel Diseases 2011, 18: 797-797. PMID: 22180343, DOI: 10.1002/ibd.21660.Peer-Reviewed Original Research